**PGN-OB1** is a [[Adalimumab|adalimumab]] variant and [[OBDS|OBDS]] [[Combination Products|drug device combination]]. Expected to treat autoimmune diseases as part of the [[Systemic Therapeutics Pipeline|Systemic Therapeutics Pipeline]]. > [!quote] PGN-OB1: liquid formulation of anti-TNF-alpha monoclonal antibody delivered with the OBDS for the treatment of autoimmune conditions > We are developing PGN-OB1 as a combination product of a variant of adalimumab and the OBDS for the treatment of inflammatory conditions. Several anti-TNF-alpha antibodies have been approved to treat a range of inflammatory conditions. However, all require either intravenous or subcutaneous injection. Adalimumab is approved for a range of inflammatory disorders and is the best-selling drug globally. An oral variant of adalimumab presents a significant opportunity for the many patients who would like to avoid painful injections. > > PGN-OB1 is currently in preclinical stage development with a formulation that we have developed and scaled to [[Good Manufacturing Practice|GMP]] grade material. > > Source: <https://www.bioratherapeutics.com/pipeline/systemic-therapeutics>